Company Development
Jul 2021

AND017 – Phase II study China central IRB approval


Jun 2021

AND019 – Phase I study NMPA Pre-IND


Jan 2021

AND017 – Phase II study FDA IND approval


Aug 2020

AND017 – China Phase I study complete


Aug 2020

Ground broken on a 200,000 square foot administrative office space and manufacturing facility in Hangzhou


Nov 2019

"Innovative Entrepreneurship Team of Zhejiang Province" award


Oct 2019

Nobel Prize of Physiology or Med awarded to the MoA of AND017


Sep 2019

Decheng Capital invested exclusively on Kind


Aug 2019

AND017 – Australia Phase I study complete


May 2019

AND019 – Initiation of IND enabling study


Apr 2019

AND017 – China Phase I study IND approval


Jul 2018

12.5 million non-dilutive grant awarded by Yuhang Industrial Fund


Nov 2017

AND017 – Patent filed in China



2015

R&D Initiation


July 15, 2014

Founded at Yuhang District, Hangzhou